Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Zydus Lifesciences Limited
Press Release Sep 10 2024
Business
Sep 10 2024
5 min read

Press Release Sep 10 2024

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 10, 2024, titled "Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".

View Attachment